<DOC>
	<DOCNO>NCT01658605</DOCNO>
	<brief_summary>GSK1605786 oral antagonist specific chemokine receptor CCR9 development treatment small bowel colonic Crohn 's disease ( CD ) . The purpose Phase II proof concept study investigate efficacy safety GSK1605786 ( 500 mg twice daily ) administer orally 16 week treatment patient active ulcerative colitis ( UC ) . A key secondary objective understand mechanism GSK1605786 act end sample collect confirm degree inhibition CCR9 T lymphocytes blood patient , explore relationship concentration drug change lymphocyte antigen presenting cell population peripheral circulation colon . Patients recruit specified investigational site invite participate optional sub-study explore effect GSK1605786 traffic technetium label T cell use Single Photon Emission Computerized Tomography ( SPECT ) . Specifically , technique use follow traffic large intestine thymus finding link pharmacokinetics GSK1605786 , receptor occupancy clinical efficacy outcome</brief_summary>
	<brief_title>A Study Investigate Efficacy Safety GSK1605786 Treatment Patients With Active Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Male female age 18 time signing informed consent . A female subject childbearing potential eligible participate agrees use one contraception method list Section 8.1 appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception completion followup visit . Capable give write informed consent , include compliance requirement restriction list consent form , prior screen procedure include discontinuation prohibit medication . At screen ( visit 1 ) : patient clinical history examination suggestive active UC least 3 month despite least 2 week treatment oral &gt; 2.4g/day mesalazine / mesalamine equivalent . At screening/randomization ( visit 2 ) : Presence active UC spread beyond rectum ( inflammation extend ≥ 15cm anal verge ) evidence flexible sigmoidoscopy colonoscopy screen window . AND MAYO score 5 10 inclusive . AST ALT &lt; 2xULN ; alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN If female , pregnant , positive pregnancy test breastfeeding . Confirmed diagnosis celiac disease , follow glutenfree diet manage symptom suspect celiac disease subject positive serologic test Tissue transglutaminase , tTG . Subjects received immunisation live vaccine e.g . measles , mumps , rubella ( MMR vaccine ) , oral polio , varicella , yellow fever , within 4 week screen throughout study , exception influenza vaccine . Known suspicion CD , indeterminate colitis , microscopic colitis , ischaemic colitis radiationinduced colitis , base medical history , endoscopy and/or histological finding . Subjects imminent need surgery UC opinion investigator . Subjects assessment MAYO score likely confound previous surgery ( example colectomy , ileostomy , colostomy rectal pouch ) . Subjects require enteral parenteral feeding . Use prohibit medication within specify timeframes ( see Section 9 ) . 5Aminosalicylic acid enema : within 2 week screen throughout study Topical ( suppository ) 5Aminosalicylic acid : screening throughout study Biologic use : within 12 week screen throughout study Corticosteroids use : Oral , rectal parenteral corticosteroid within 4 week screen throughout study Antibiotics : Intravenous antibiotic within 8 week screen throughout study ( oral antibiotic permit used &gt; 4 week stable dose ≥2 week prior screen ) Probiotics : within 4 week screen ( patient initiate probiotic prebiotics 4 week prior screen continue use throughout study ) NSAIDs : Within 7 day screen throughout study ( except low dose aspirin ( ≤325 mg/day ) may continue cardioprotection ) Digoxin : related cardiac glycoside ( e.g . digitoxin , deslanoside , lanatoside C , metildigoxin ) use time screen throughout study . Known HIV infection A positive HBsAg , AntiHBc , Hepatitis C antibody result screen document positive result within 3 month screen . Known varicella , herpes zoster , severe viral infection within 6 week screen . Active latent tuberculosis ( TB ) infection : The subject history TB disease latent TB infection , absence document adequate therapy . Suspicion current TB disease ( include extra pulmonary TB disease tuberculosis enteritis ) latent tuberculosis infection , evidence positive QuantiFERONTB Gold test , TSPOT.TB test . Current chronic history liver disease know hepatic biliary abnormality include primary sclerosing cholangitis ( exception Gilbert 's syndrome asymptomatic gallstone ) . QTc ≥450 msec ( ≥480msec Bundle Branch Block ) . either QTcb QTcf , machine manual overread , male female . The QT correction formula use determine exclusion discontinuation throughout study . base single QTc value ECG obtain brief recording period . The subject concurrent illness disability may affect interpretation clinical data , otherwise contraindicate participation clinical study ( e.g. , unstable cardiovascular , autoimmune , congenital acquire immunodeficiency , renal , hepatic , pulmonary , endocrine , metabolic , gastrointestinal , haematologic , neurological condition mental impairment ) . The subject current evidence , treat malignancy within past 5 year ( localise basal cell , squamous cell skin cancer , cervical dysplasia , cancer situ resect ) . Use investigational drug within 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) prior screen Medical history sensitivity component GSK1605786 ( microcrystalline cellulose , colloidal silicon dioxide , crospovidone , magnesium stearate , gelatin ) . Prior exposure GSK1605786 : Any previous exposure GSK1605786 ( formerly ChemoCentryx compound CCX282B ) . Known positive stool culture enteric pathogen Positive immunoassay C. difficile . Where participation study would result donation blood blood product excess 500 mL within 56 day period ( exception subject involve optional scintigraphy substudy , 700 mL blood collect duration study , include extra assessment may require ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>GSK1605786</keyword>
	<keyword>ulcerative colitis</keyword>
	<keyword>CCR9 antagonist</keyword>
	<keyword>proof concept</keyword>
</DOC>